June 13 (Reuters) – Johnson & Johnson: * NEW TALVEY® (TALQUETAMAB-TGVS) PLUS DARZALEX FASPRO® (DARATUMUMAB AND HYALURONIDASE-FIHJ) DATA DEMONSTRATE THE STRENGTH OF A BISPECIFIC COMBINATION IN
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
US Open champ Zverev grabs early Davis Cup win for Germany
VIDEO SHOWS: GERMANY-CROATIA DAVIS CUP SECOND QUALIFYING ROUND TIE HIGHLIGHTS WITH ALEXANDER ZVEREV BEATING MATEJ…
Soccer-Dortmund beat Stuttgart 1-0 to go top of Bundesliga
Sept 19 (Reuters) - Maximilian Beier struck the only goal as Borussia Dortmund beat VfB…
Trump says he will appoint a new AI adviser, without providing details
WASHINGTON, Sept 19 (Reuters) - U.S. President Donald Trump said in a social media post…
